BEACOPP

BEACOPP is a chemotherapy regimen for treatment of Hodgkin's lymphoma in Stages > II developed by the German Hodgkin Study Group. Patients typically receive treatment in cycles of 21 days with no drugs given on days 16-21. There also exists a more intensive regimen with cycles of 14 days. Usually a therapy consists of eight, sometimes six cycles. In some countries BEACOPP still is experimental, in others (e.g. Germany and Austria) it is a standard therapy. In the United States, ABVD (or Stanford V) is generally given instead, because BEACOPP is thought to induce more secondary neoplasias (such as leukemias)^{[citation needed]}. This has not been proven after 10 years of experience in other countries. Some consider that the BEACOPP regimen is not generally given for cost reasons^{[citation needed]}; it is indeed more expensive as it requires G-CSF support. However, BEACOPP delivers approximately 10-15% more cures in advanced Hodgkin's disease (IIB+risk factors or stages III and IV)^{[citation needed]}.

m² = body surface

i.v. = intravenous

BEACOPP basic:

(B)leomycin	10 mg/m²	i.v.	day 8
(E)toposide	100 mg/m²	i.v.	day 1-3
(A)driamycin	25 mg/m²	i.v.	day 1
(C)yclophosphamide	650 mg/m²	(i.v.)	day 1
Vincristin(=(O)ncovin)	1,4 mg/m² (max 2 mg)	i.v.	day 8
(P)rocarbazine	100 mg/m²	orally	day 1-7
(P)rednisone	40 mg/m²	orally	day 1-14

BEACOPP escalated:

Bleomycin	10 mg/m²	i.v.	day 8
Etoposide	200 mg/m²	i.v.	day 1-3
Adriamycin (=Doxorubicin)	35 mg/m²	i.v.	day 1
Cyclophosphamide	1250 mg/m² KO/day	i.v.	day 1
Vincristine	1,4 mg/m² (max 2 mg)	i.v.	day 8
Procarbazine	100 mg/m²	orally	day 1-7
Prednisone	40 mg/m²	orally	day 1-14

See also

• German Hodgkin Study Group
• Stanford V
• ABVD